Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study.

"CONFLICTS OF INTEREST Guarantor of the article: Shao-Rui Hao, MD, Shan-Yan Zhang, MD, Jiang-Shan Lian, MD, Xi Jin, MD, and Cheng-Yin Ye, PhD, contributed equally to this article. Yi-Da Yang, MD, accepts full responsibility for the conduct of the study and had full access to the data and control of the decision to publish. Specific author contributions: Y.-D.Y., T.-B.L., J.-F.S., and L.-J.L. designed the study. S.-R.H. and S.-Y.Z. managed the full deidentified data set. S.-R.H. and C.-Y.Y. performed the statistical analyses. S.-R.H. and J.-S.L. authored the initial draft of the manuscript. X.J. and Y.-D.Y. critically revised the manuscript. All authors were involved in the review and interpretation of data and approved the final copy. Financial support: This work was supported by National Natural Science Foundation of China (81700549) and National Major Science and Technology Research Projects for the Control and Prevention of Major Infectious Diseases in China (2017ZX10202202). Potential competing interests: All the authors have no conflict of interest to declare.Study HighlightsWHAT IS KNOWN✓ Liver enzyme elevation was observed in patients with COVID-19.✓ The features of the liver enzyme elevation subset in COVID-19 remain unknown.WHAT IS NEW HERE✓ Of patients with COVID-19, 28.2% presented with elevated liver enzyme levels on admission.✓ Most liver enzyme elevations were mild, and no liver failures were observed.✓ Being male, overweight, and with a history of smoking were risk factors of liver enzyme elevation.✓ The liver enzyme elevation group had less pharyngalgia and more diarrhea.✓ Early medical intervention likely neutralized the effects that resulted from the liver enzyme elevation."

"Financial support: This work was supported by National Natural Science Foundation of China (81700549) and National Major Science and Technology Research Projects for the Control and Prevention of Major Infectious Diseases in China (2017ZX10202202)."